Table 1.
Included trials in the meta-analysis of α7 nicotinic agonists for cognitive dysfunction in schizophrenia and Alzheimer’s disease.
| First author | Year | Agonist | Dose(s) (total mg/day) | Design | Duration | N | Subject diagnosis | Smoking status | Cognitive outcomes in meta-analysis | References |
|---|---|---|---|---|---|---|---|---|---|---|
| Haig | 2016 | ABT-126 | 10, 25 | Parallel | 12 weeks | 207 | SCZ | Mix | OCI, P, VeL, ViL, WM, EF, A, SC | (Haig et al., 2016) |
| Florian | 2016 | ABT-126 | 25, 75 | Parallel | 24 weeks | 434 | AD | Mix | OCI | (Florian et al., 2016) |
| Gault | 2015 | ABT-126 | 5, 25 | Parallel | 12 weeks | 274 | AD | Mix | OCI | (Gault et al., 2015) |
| Keefe | 2015 | EVP-6124 | 0.27, 0.90 | Parallel | 12 weeks | 319 | SCZ | Mix | OCI, P, A, WM, VeL, ViL, EF, SC | (Keefe et al., 2015) |
| Preskorn | 2014 | EVP-6124 | 0.30, 1.0 | Parallel | 3 weeks | 21 | SCZ | Mix | OCI, WM, EF, SC, ViL | (Preskorn et al., 2014) |
| Deutsch | 2013 | Galantamine + choline | Gal: 24 Chol: 2000 |
Parallel | 16 weeks | 43 | SCZ | Mix | P, A, WM, VeL, ViL | (Deutsch et al., 2013) |
| Freedman | 2008 | GTS-21 | 150, 300 | Crossover | 4 weeks | 31 | SCZ | NS | P, A, WM, VeL, ViL, EF | (Freedman et al., 2008) |
| Olincy | 2006 | GTS-21 | 112.5, 225 | Crossover | 1 day | 12 | SCZ | NS | OCI, A, WM, VeL, ViL, P, L | (Olincy et al., 2006) |
| Umbricht | 2014 | RG3487 | 5, 15, 50 | Parallel | 8 weeks | 215 | SCZ | Mix | OCI, P, A, VeL, ViL, EF, SC | (Umbricht et al., 2014) |
| Lieberman | 2013 | TC-5619 | 25 | Parallel | 12 weeks | 185 | SCZ | Mix | OCI, EF, P, A, VeL, ViL, WM, SC | (Lieberman et al., 2013) |
| Walling | 2016 | TC-5619 | 5, 50 | Parallel | 24 weeks | 477 | SCZ | Mix | OCI | (Walling et al., 2016) |
| Shiina | 2010 | Tropisetron | 10 | Parallel | 8 weeks | 40 | SCZ | Mix | WM, EF, A | (Shiina et al., 2010) |
| Zhang | 2012 | Tropisetron | 5, 10, 20 | Parallel | 10 days | 40 | SCZ | NS | OCI, WM, P, L, A, VeL, ViL | (Zhang et al., 2012) |
| Shim | 2012 | Varenicline | 2 | Parallel | 8 weeks | 120 | SCZ | Mix | A, P, WM, EF | (Shim et al., 2012) |
| Kim | 2014 | Varenicline | 2 | Crossover | 6 weeks | 66 | AD | NS | OCI, ViL, P, A, WM | (Kim et al., 2014) |
| Smith | 2016 | Varenicline | 2 | Parallel | 8 weeks | 87 | SCZ | S | OCI, P, A, WM, VeL, ViL, EF | (Smith et al., 2016) |
| Roh | 2014 | Varenicline | 1 | Crossover | 1 day | 30 | SCZ | NS | A, P, WM | (Roh et al., 2014) |
| Hong | 2011 | Varenicline | 1 | Parallel | 8 weeks | 69 | SCZ | Mix | OCI, A, P | (Hong et al., 2011) |
Abbreviations: OCI, overall cognitive index. P, speed of processing, VeL, verbal learning; ViL, visual learning; WM, working memory; EF, executive function; A, attention; SC, social cognition; L, language; NS, non-smoking; S, all smokers; AD, Alzheimer’s disease; SCZ, schizophrenia.